Ikena Oncology, Inc. is a targeted oncology company, which develops medicines for patient groups with specific unmet needs. The Company lead targeted oncology product candidate, IK-930, is an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also combining IK-930 with other targeted therapies across several indications, including EGFR mutated non-small cell lung cancer and KRAS mutated cancers. The Company has initiated a first in human Phase I clinical trial of IK-930 in patients with advanced solid tumors with a high frequency of Hippo pathway alternations. Its clinical-stage programs also include product candidates in development to target immune signaling in the tumor microenvironment. IK-175 is an oral inhibitor of aryl hydrocarbon receptor, which it is evaluating in a Phase Ia/Ib clinical trial in solid tumors and in urothelial carcinomas as monotherapy and in combination with nivolumab.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Annual Dividend Rate
Price/Cash Flow (TTM)